Using a new imaging agent to detect bone tumors
[68Ga]Ga-P15-041 PET/CT for Diagnosis and Prognostic Evaluation in Variety of Bone Tumors
This study is testing a new imaging agent to see if it can help doctors find bone tumors earlier and more accurately in patients.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Fujian Medical University Academic / other |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT06455722 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of a novel Gallium-68 labeled radiopharmaceutical, [68Ga]Ga-P15-041, for imaging various types of bone tumors, including both primary and metastatic forms. The study aims to improve early diagnosis of bone tumors, which is crucial for implementing effective treatment strategies. Participants will undergo imaging procedures to assess the distribution and effectiveness of the new agent compared to existing methods. The trial is being conducted at the First Affiliated Hospital of Fujian Medical University.
Who should consider this trial
Good fit: Ideal candidates include individuals with suspected or confirmed primary or metastatic bone tumors who can provide informed consent.
Not a fit: Patients who are pregnant, breastfeeding, or have known allergies to bisphosphonates may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate detection of bone tumors, improving treatment outcomes for patients.
How similar studies have performed: While the use of Gallium-68 labeled agents is established, this specific application of [68Ga]Ga-P15-041 is novel and has not been extensively tested in clinical settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * suspected or confirmed primary bone tumors or metastatic bone tumors * signed written consent * available other examinations such as bone scan or enhanced CT within 2 weeks Exclusion Criteria: * pregnancy * breastfeeding * known allergy against bisphosphonate
Where this trial is running
Fuzhou, Fujian
- Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (Recruiting)
Study contacts
- Principal investigator: Weibing Miao, MD — First Affiliated Hospital of Fujian Medical University
- Study coordinator: Weibing Miao, MD
- Email: miaoweibing@126.com
- Phone: +86-0591-87981618
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.